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Abstract
Clinical trials often evaluate multiple outcome variables to form a com-
prehensive picture of the effects of a new treatment, and use this multidi-
mensional insight to make a decision about treatment superiority. Com-
mon statistical procedures to make these superiority decisions with multi-
ple outcomes have three important shortcomings: 1.) Outcomes are often
modelled individually, and consequentially fail to consider the relation be-
tween outcomes; 2.) Superiority is often defined as a relevant difference
on a single, any, or all outcomes(s); and lacks a compensatory mechanism
that allows positive effects on some outcomes to outweigh negative effects
on other outcomes; 3.) A priori sample size computation relies on multiple
pieces of information that are often not or only partially available at the
time of study design, thereby potentially undermining accuracy. These
shortcomings may result in trials including too many patients or leading
to erroneous decisions. In this paper, we suggest solutions to each of the
introduced shortcomings by proposing 1.) a Bayesian multivariate model
for the analysis of correlated binary outcomes; 2.) a decision criterion
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with a compensatory mechanism; and 3.) an adaptive stopping rule that
relies on interim monitoring to terminate data collection timely.
1 Introduction
Clinical trials often include multiple outcome variables to form a comprehensive
picture of a new treatment compared to a control treatment. Collected data
about efficacy (e.g. reduction of disease symptoms), safety (e.g. side effects),
and other relevant aspects contribute to a multidimensional insight in the effects
of the treatment. All these outcomes are subsequently combined into a single,
coherent decision regarding treatment superiority.
A decision procedure, including the design of the trial, the analysis, and the
final decision rule should efficiently lead to clinically relevant decisions. Efficient
decisions procedures serve two aims: They should have acceptable error rates
while minimizing the number of patients in the trial. The emphasis on efficiency
is motivated by several considerations, such as ethical concerns, limited access to
participants (e.g. due to rare diseases) and other difficulties to enroll a sufficient
number of participants. In the current paper, we address clinical relevance and
efficiency in the context of multiple binary outcomes and propose a framework
for statistical decision-making.
Statistical procedures to arrive at a superiority decision have two compo-
nents: 1.) A statistical model for the collected data; and 2.) A decision rule to
evaluate the modelled data in terms of superiority. The FDA recommends to
model all outcomes individually with multiple univariate distributions, resulting
in a superiority conclusion when the treatment performs better on a.) the most
important outcome; b.) any of the outcomes, or c.) all outcomes (Food and
Drug Administration, 2017). In the remainder of the paper, the latter decision
rules are referred to as the Single rule, Any rule, and All rule respectively.
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Figure 1: Differentiation of two bivariate posterior distributions (diago-
nally) versus the differentiation of their univariate distributions (horizon-
tally/vertically). Each distribution reflects the plausibility of the treatment
effects θ1 and θ2 after observing the data.
Despite this recommendation, decision procedures based on the evaluation of
individual outcomes have a number of potential shortcomings. The first problem
may be attributed to the univariate nature of the models. Univariate modelling
fails to consider the relation between outcomes, potentially resulting in lower
efficiency. Statistical procedures that fail to properly combine the effects on the
different outcomes may be unable to find conclusive evidence for superiority,
which we demonstrate with an example in Figure 1. The two displayed bivari-
ate posterior distributions reflect the effects on two outcomes for a Treatment
and a Control group. The figure demonstrates how data may provide consid-
erable evidence for a treatment difference when the combination of outcomes
is considered, while evidence for a treatment effect based on one or multiple
individual outcomes is much lower. To be more concrete: The univariate dis-
tributions projected on the horizontal and vertical axes overlap too much to
clearly differentiate the two treatments on the individual outcomes θ1 and θ2
respectively, while the bivariate treatment distributions can be separated when
considering a diagonal perspective. Such a multivariate treatment difference is
only detectable when multiple outcomes are modelled jointly.
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A second problem stems from defining superiority as a specific combination of
univariate criteria on individual outcomes, such as the All or Any rules. These
definitions of superiority evaluate positive effects only, thereby ignoring rela-
tions between positive and negative effects. Taking such relations into account
increases the flexibility of decision-making and allows for alternative decision
rules. Highly relevant for clinical decision-making is a rule with a compensatory
mechanism, which concludes superiority when positive effects outweigh nega-
tive effects (Murray et al., 2016). Specifically, a compensatory decision rule
may deem a treatment with a small negative effect on one outcome superior, as
long as this negative effect is compensated by a larger positive effect on another
outcome. A compensatory mechanism may increase the efficiency of decision-
making, since the rule can combine information from several outcomes into an
identifiable treatment effect when none of the individual effects is sufficiently
large to be detected (O’Brien, 1984; Tang et al., 1989; Pocock et al., 1987). This
situation is also displayed in Figure 1. Jointly modeling the two outcomes using
a compensatory decision rule with equal weights (which will be discussed later)
can detect the clear separation of the two bivariate distributions in Figure 1, and
will conclude superiority of the Treatment group as desired. The compensatory
rule can be naturally extended with impact weights. Impact weights conform
to the idea that some treatment effects may be more relevant for the decision
than others and further increase the flexibility and clinical relevance.
Despite the intuitive character of compensatory decision-making, the afore-
mentioned decision rules (Single, All, Any) do not formally include such a mech-
anism and have taken impact weights to the extreme: They assume that the
success rate of one specific (Single rule) or non-specific (Any rule) outcome solely
determines superiority independent of the results on other outcomes, or that all
outcomes have the same impact on the decision (All rule).
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As another potential issue, it is unclear how many observations are needed
to detect a treatment effect. Trials often estimate the required number of ob-
servations prior to data collection, using a procedure referred to as a priori
sample size estimation. This procedure requires multiple pieces of information
that are usually not or only partially available in advance, such as treatment
differences and correlations between them. Although the missing information
could be replaced by estimates, their accuracy is essential for proper a priori
sample size estimation. Inaccuracies are problematic for decision error rates, as
the estimates themselves determine the number of patients included in the trial.
Overestimation of a single treatment difference results in a too small sample to
obtain the desired level of power. In contrast, underestimating a treatment
difference results in a larger sample than strictly necessary and produces subop-
timal efficiency. These uncertainties accumulate in trials with multiple outcomes
since the number of unknowns increases, thereby complicating the planning of
the trial.
The three aforementioned shortcomings of analyzing outcomes individually
potentially result in trials including too many patients or leading to erroneous
decisions. Several alternatives that take the relation between binary outcomes
into account in the modelling procedure have been proposed (e.g Whitehead
et al., 2010; Sozu et al., 2010). The majority of these alternatives relies on large
sample approximations, such as z-tests (see for an exception Murray et al.,
2016). These tests have limited applicability, since the validity of z-tests for
small samples is hard to judge. Moreover, most of these alternatives are based
on some variant of the All rule and suffer from the introduced problems with
this decision rule. In the current paper, we propose a flexible alternative and
aim to solve the introduced problems with a Bayesian framework consisting of
three elements:
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1. A multivariate model for multiple binary outcomes that explicitly models
the correlations between the outcomes;
2. A decision rule with a compensatory mechanism that allows a small nega-
tive effect on one outcome to be compensated by a large effect on another
outcome;
3. An adaptive method to compute sample sizes by monitoring data and stop-
ping the trial as soon as evidence for a treatment difference is sufficiently
large.
The remainder of the paper is structured as follows. In Section 2, we present
a multivariate approach to the analysis of multiple binary outcomes. We dis-
cuss the evaluation of treatment differences using multiple decision rules and
outline their statistical properties in Section 3. We address several considera-
tions regarding trial design in Section 4 and demonstrate how to to implement
the framework in Section 5. The framework is evaluated in Section 6, and we
discuss limitations and extensions in Section 7.
2 A model for multivariate Bayesian analysis of
multiple binary outcomes
We start the introduction of our framework with some notation. We consider
the binary response xj,i,k to treatment j by patient i on outcome k, where
i ∈ {1, . . . , nj}, k ∈ {1, . . . ,K}, and j ∈ {T,C} (i.e., Treatment and Control).
Further, response xj,i,k ∈ {0, 1}, where 0 and 1 indicate failure and success
respectively. The probability of success on outcome k and treatment j in the
population will be denoted by θj,k and is assumed to be equal for all patients.
We use vector θj = (θj,1, . . . , θj,K) to refer to the success probabilities of all K
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outcomes for treatment j.
To facilitate the multivariate analysis of multiple outcomes, two transforma-
tions are useful to consider. First, the difference between success probabilities of
treatments T and C is typically of main interest. For outcome k, this difference
is defined as the difference between the success probabilities of treatments T and
C, i.e. δk = θT,k − θC,k. Vector δ = (δ1, . . . , δK) then denotes the treatment
differences on K outcomes.
Second, the vector θj fails to properly reflect the relationships between dif-
ferent outcomes (i.e., the covariances). To capture these relations explicitly,
the joint response combinations and their probabilities are required. The joint
response for patient i under treatment j will be denoted by xj,i and can take
on 2K different combinations {1 . . . 11}, {1 . . . 10}, . . . , {0 . . . 01}, {0 . . . 00}. The
observed frequencies of each possible response combination for treatment j in
a dataset of nj patients are denoted by vector sj of lengthQ = 2
K . The elements
of sj add up to nj ,
∑Q
q=1 sj,q = nj . We use φj = φj,1...11, φj,1...10, . . . , φj,0...01, φj,0...00
to denote the success probabilities of these response combinations (i.e. cell
probabilities when considering a contingency table for each treatment j) in the
population. Vector φj has Q elements, and sums to unity,
∑Q
q=1 φj,q = 1.
Joint responses and probabilities are directly related to marginal responses
and probabilities. The total number of successes on outcome k for treatment
j equals the sum of observed frequencies of all joint response combinations
that indicate success on outcome k. For example, when K = 2,
∑nj
i=1 xj,i,1 =
sj,11 + sj,10. Similarly, marginal success probability θj,k is then equal to the
sum of probabilities of response combinations that indicate success on θj,k, e.g.
θj,1 = φj,11 + φj,10 for K = 2.
The remainder of this section first discusses the analysis of two outcomes
and then presents the generalization to K outcomes.
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2.1 A Bayesian model for two outcomes
With two outcomes, K = 2, the likelihood of joint response xj,i = (xj,i,1, xj,i,2)
follows a bivariate Bernoulli distribution (Dai et al., 2013):
P (xj,i|φj) =bivariate Bernoulli(xj,i|φj) (1)
=φj,11
xj,i,1xj,i,2φj,10
xj,i,1(1−xj,i,2)φj,01(1−xj,i,1)xj,i,2φj,00(1−xj,i,1)(1−xj,i,2),
The bivariate Bernoulli distribution in Equation 1 is a specific parametriza-
tion of the multinomial distribution. A dataset of nj observations, summarized
by cell frequencies in sj then follows a multinomial distribution with parameters
φj :
P (sj |φj) =
nj∏
i=1
P (xj,i|φj) (2)
=Multinomial(sj |φj)
∝φj,11sj,11φj,10sj,10φj,01sj,01φj,00sj,00 ,
(3)
A Dirichlet distribution is a natural choice to model prior information about
response probabilities φj , since the Dirichlet distribution is a conjugate prior
distribution for a multinomial likelihood. The prior distribution of φj has hy-
perparameters αj
0 = (α0j,11, α
0
j,10, α
0
j,01, α
0
j,00), that reflect the amount of prior
information for each of the cell probabilities in φj (a discussion on the specifi-
cation of hyperparameters can be found in Section 4.1). The prior distribution
of φ is proportional to the following density:
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P (φj) =Dirichlet(φj |α0j ) (4)
∝φj,11α
0
j,11−1φj,10α
0
j,10−1φj,01α
0
j,01−1φj,00α
0
j,00−1,
Given the conjugacy of the bivariate Bernoulli and the Dirichlet distri-
butions, the posterior distribution of φj is proportional to the likelihood of
sj times the prior of φj and follows a Dirichlet distribution with parameters
αnj = α
0
j + sj :
P (φj |sj) ∝P (sj |φj)× P (φj |α0j ) (5)
∝φj,11sj,11φj,10sj,10φj,01sj,01φj,00sj,00 × φj,11α
0
j,11−1φj,10α
0
j,10−1φj,01α
0
j,01−1φj,00α
0
j,00−1
=φj,11
αnj,11−1φj,10α
n
j,10−1φj,01α
n
j,01−1φj,00α
n
j,00−1
∝ Dirichlet(φj |α0j + sj)
To make the modelling procedure of multiple binary outcomes more intu-
itive, we might look at posterior information in a different way and consider
the distribution of joint success probabilities θj rather than the posterior dis-
tribution of joint response probabilities φj . Considering θj draws a parallel to
the univariate situation, where binary response xj,i,k is usually modelled with a
Bernoulli distribution, combined with a conjugate beta prior distribution, and
results in a beta posterior distribution of θj,k. Similarly, the joint posterior
distribution of θj,1 and θj,2 follows a bivariate beta distribution (Olkin and
Trikalinos, 2015):
P (θj |αnj ) =
1
B(αnj )
∫
Ω
φj,11
αnj,11−1 × (θj,1 − φj,11)αnj,10−1× (6)
(θj,2 − φj,11)αnj,01−1 × (1− θj,1 − θj,2 + φj,11)αnj,00−1∂φj,11,
9
where Ω =φj,11 : max(0, θj,1 + θj,2 − 1) < φj,11 < min(θj,1, θj,2)
The bivariate beta distribution can be obtained by transforming the Dirichlet
distribution of φj . Specifically, reparametrizing φj in terms of θj and integrat-
ing φj,11 out transforms the Dirichlet distribution of posterior φj to a bivariate
beta posterior of success probabilities θj (Olkin and Trikalinos, 2015).
In contrast to the univariate situation, the bivariate beta distribution does
not follow directly from a conjugate procedure. The computational part of
a procedure that exploits conjugacy relies on the Dirichlet distribution, since
posterior computation formally requires explicit specification of the relation
between success probabilities (i.e. φj,11).
The bivariate beta distribution also plays a role in the final superiority de-
cision, which relies on a sample of posterior draws from the distribution of
treatment difference δ. Since we cannot sample from the distributions of θj or
δ directly, the desired sample can be obtained via a two-step transformation
of the Dirichlet posterior distribution of φj . Drawing a sample from the pos-
terior distribution of φj and using the property that θj,1 = φj,11 + φj,10 and
θj,2 = φj,11 + φj,01 to sum the joint response probabilities results in a sample
from the bivariate beta distribution of posterior θj . These samples from the
posterior distributions of θT and θC can be transformed to obtain the posterior
distribution of joint treatment difference δ, by subtracting draws of θC from
draws of θT , i.e. δ = θT − θC .
2.2 A Bayesian model for more than two outcomes
The introduced model can be generalized to K outcomes to obtain draws from
the K-variate posterior distribution of the treatment difference δ = (δ1, . . . , δK).
The likelihood of joint response xj,i follows a K-variate Bernoulli distribution:
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P (xj,i|φj) =multivariate Bernoulli(xj,i|φj) (7)
=φj,1...11
xj,1...xj,Kφj,1...10
xj,1...xj,K−1(1−xj,K) × · · ·×
φj,0...01
(1−xj,1)...(1−xj,K−1)xj,Kφj,0...00(1−xj,1)...(1−xj,K)
The likelihood of nj joint responses in sj follows a 2
K-variate multinomial
distribution:
P (sj |φj) =Multinomial(sj |φj) (8)
∝ φj,1...11sj,1...11φj,1...10sj,1...10 × · · · × φj,0...01sj,0...01φj,0...00sj,0...00
Prior information about φj is modelled by a 2
K-variate Dirichlet distribution
with hyperparameters α0j :
P (φj |α0j ) =Dirichlet(φj |α0j ) (9)
∝φj,1...11α
0
j,1...11φj,1...10
α0j,1...10 × · · · × φj,0...01α
0
j,0...01φj,0...00
α0j,0...00
The resulting posterior Dirichlet distribution of φj with parameters α
n
j =
α0j + sj can be reparametrized to a K-variate beta distribution of θj with
parameters αnj by integrating out all 2
K − K − 1 probabilities of successes
on more than one outcome. If θj follows a K-variate beta distribution, each
set of K − 1 variables then follows a K − 1-variate beta distribution and each
individual variable k follows a univariate beta distribution (Olkin and Trikalinos,
2015). The distribution of δ then follows from transforming the marginal success
probabilities to the probabilities of the treatment difference δk = θT,k − θC,k,
similar to the bivariate situation.
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3 Decision rules for multiple binary outcomes
The current section discusses how the model from Section 2 can be used to
make treatment superiority decisions. We will outline multiple decision rules
with two outcomes first, and then discuss their generalizations to more than
two outcomes.
3.1 Decision rules for two outcomes
For two outcomes, K = 2, treatment superiority is defined by the posterior
mass in a specific subset of the complete parameter space of δ = (δ1, δ2). The
complete parameter space will be denoted by S ⊂ (−1, 1)2, and the superiority
space will be denoted by SSup ⊂ S. Superiority is concluded when a sufficiently
large part of the posterior distribution of δ falls in the superiority region SSup:
P (δ ∈ Ssup|sT , sC , α0T , α0C) > pcut (10)
where pcut reflects the decision threshold to conclude superiority.
Different partitions of the parameter space define different superiority cri-
teria to distinguish two treatments. Within our framework, superiority of the
Single, Any, and All rules is graphically presented in Figure 2 and defined as
follows:
1. Single rule: The Single rule concludes superiority when there is sufficient
evidence that the a priori specified primary outcome k has a treatment
difference larger than zero. The superiority region is displayed in Figure
2a and denoted by:
SSingle(k) = {(δ1, δ2)|δk > 0} (11)
2. Any rule: The Any rule results in superiority when there is sufficient
12
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(a) Single (outcome 1)
−1.0 −0.5 0.0 0.5 1.0
−1.0
−0.5
0.0
0.5
1.0
δ1
δ 2
(b) Any
−1.0 −0.5 0.0 0.5 1.0
−1.0
−0.5
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0.5
1.0
δ1
δ 2
(c) All
−1.0 −0.5 0.0 0.5 1.0
−1.0
−0.5
0.0
0.5
1.0
δ1
δ 2
w1 < w2
w1 > w2
(d) Compensatory
Figure 2: Rejection regions of various decision rules. The Compensatory rule
reflects w = (0.5, 0.5).
evidence that one of the outcomes has a treatment difference larger than
zero. The treatment difference on the other outcome is irrelevant and can
be negative, positive or zero. The superiority region is displayed in Figure
2b and denoted by:
SAny = {(δ1, δ2)|δ1 > 0 or δ2 > 0} (12)
3. All rule: The All rule results in superiority when both outcomes of treat-
ment T show improvement over treatment C. The superiority region is
displayed in Figure 2c and denoted by:
SAll = {(δ1, δ2)|δ1 > 0 and δ2 > 0} (13)
Next to facilitating these common decision rules, our framework allows for
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alternative decision rules, such as the Compensatory decision rule:
4. Compensatory rule: The Compensatory rule uses a weighted sum of treat-
ment differences, where w = (w1, w2) reflect the weights for outcomes 1
and 2 respectively. A treatment is superior when the weighted sum of
treatment differences is larger than zero. The superiority region is dis-
played in Figure 2d and denoted by:
SCompensatory(w1, w2) = {(δ1, δ2)|w1δ1 + w2δ2 > 0} (14)
Weight wk regulates the impact of the k-th outcome on the decision, which
we will discuss in more detail in Section 4.2. The visual effect of the chosen
weights w is displayed in Figure 2d. Different combinations of weights w1
and w2 rotate the superiority region of the Compensatory rule. When
w1 < w2, the superiority region is rotated clockwise towards the y-axis,
while w2 > w1 rotates the superiority region counterclockwise towards the
x-axis.
From our discussion of the different decision rules, a number of relationships
between them can be identified. First, the superiority regions of the Single, All
and Compensatory rules are subsets of the superiority region of the Any rule,
and the superiority region of the All rule is also a subset of the other three rules,
i.e. SAll ⊂ SSingle,SCompensatory ⊂ SAny. This property directly translates to
the amount of evidence in favor of treatment T : The posterior probability of
the Any rule is always largest, while the posterior probability of the All rule is
always smallest:
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P (SAny|sT , sC ,α0T ,α0C) > (15)
(P (SSingle|sT , sC ,α0T ,α0C), P (SCompensatory|sT , sC ,α0T ,α0C)) >
P (SAll|sT , sC ,α0T ,α0C)
Second, note that the Compensatory and Single rules are special cases of
a more general weighted linear combination of outcomes. The Single rule has
weight wk = 1 for primary outcome k and wl = 0 for other outcome l, while the
Compensatory rule has wk > 0 for all k and
∑K
k=1 wk = 1.
3.2 Decision rules for more than two outcomes
The generalization of the discussed decision rules to K outcomes is straight-
forward. The complete parameter space of δ = (δ1, . . . , δK) extends to S ⊂
(−1, 1)K . The superiority regions of the introduced decision rules are defined
as follows:
1. Single rule: SSingle(k) = {δ|δk > 0}
2. Any rule: SAny = {δ|max(δ > 0)}
3. All rule: SAll = {δ|min(δ > 0)}
4. Compensatory rule: SCompensatory(w) = {δ|
∑K
k=1 wkδk > 0} with wk ≥
0, and
∑K
k=1 wk = 1.
4 Design considerations
The current section elaborates on design choices for a study that aims to apply
our proposed analysis framework. The design aspects under consideration are
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the specification of prior hyperparameters α0j , the specification of weights w of
the Compensatory rule, and the setup of an adaptive design.
4.1 Specification of prior hyperparameters α0j
As outlined in section 2, our model for multiple correlated binary outcome vari-
ables is proportional to the product of a multivariate Bernoulli and a (conjugate)
Dirichlet prior. The prior distribution contains hyperparameters α0j which have
to be specified in advance of data analysis. Specifying hyperparameters is a non-
trivial task, provided that they reflect distinct aspects of the prior distribution
and impact the posterior distribution of δ as well as the superiority decision.
Let us redefine α0j as n
0
jφ
0
j to reflect these aspects more clearly and pro-
vide an intuitive specification of prior information. Here n0j and φ
0
j reflect the
amount of prior information and the prior means of joint response probabilities
φj repectively. Prior means φ
0
j relate directly to the prior means of joint suc-
cess probabilities θ0j and the prior mean treatment difference δ
0. Prior means of
response probabilities sum to prior means of marginal success probabilities, e.g.
θ0j,1 = φ
0
j,11 + φ
0
j,10. The prior mean treatment difference equals the difference
between the prior means of marginal success probabilities, e.g. δ0k = θ
0
T − θ0C .
If we consider the prior distribution of joint success probabilities θj rather
than the prior distribution of joint response probabilities φj , we might facilitate
hyperparameter specification. That is, joint success probabilities θj and treat-
ment differences δ are closely related, more likely to be available a priori, and
usually more intuitive to work with than cell probabilities φj in particular when
K increases. Here we can utilize the equivalence of the Dirichlet and multivari-
ate beta parameters discussed in Section 2, and consider that θj a priori follow
a bivariate beta distribution with hyperparameters α0j = n
0
jφ
0
j . Note that the
multivariate beta distribution cannot be formally used as a prior distribution
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in posterior computation, since the distribution is marginalized with respect to
the information about the relation between success probabilities (i.e. φj,11 when
K = 2).
The following paragraph lists the influence of hyperparameters n0jφ
0
j on the
shape of the prior distributions of success probabilities θ0j and treatment differ-
ences δ for two outcomes (i.e. K = 2). We illustrate the influences in Figures 3
and 4.
1. The amount of prior information in n0j determines the spread of the prior
distribution of treatment j, as demonstrated in Figure 3. Large n0j results
in a peaked distribution that reflects much prior information, whereas
a small n0j results in a distribution with heavy tails that conveys little
prior information. Parameter n0j can be considered a prior sample size,
where each observation has the same influence on the decision as one joint
response xj,i.
2. Mean prior success probabilities θ0j,1 = φ
0
j,11 +φ
0
j,10 and θ
0
j,2 = φ
0
j,11 +φ
0
j,01
define the center of the prior distribution of success probabilities θj (Figure
4). Similarly, mean prior treatment differences δ01 = θ
0
T,1 − θ0C,1 and δ02 =
θ0T,2−θ0C,2 reflect the center of the prior distribution of δ. When treatments
T and C have equal prior sample sizes n0j and mean prior probabilities of
joint responses φ0j (i.e. n
0
T = n
0
C and φ
0
T = φ
0
C), the prior distribution of
the treatment difference δ is centered around the origin (i.e. δ0 = 0).
3. The size of φ0j,11 relative to θ
0
j,1θ
0
j,2 determines the prior correlation be-
tween θj,1 and θj,2 (Olkin and Trikalinos, 2015):
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ρθj,1θj,2 =
φ0j,11 − θ0j,1θ0j,2√
θ0j,1(1− θ0j,1)θ0j,2(1− θ0j,2)
(16)
As follows from Equation 16, θj,1 and θj,2 are independent a priori if
φ0j,11 = θ
0
j,1θ
0
j,2. The contour of the bivariate beta distribution is then
circle or ellipse-shaped with the major axis in the horizontal or vertical
direction. A non-zero correlation (φ0j,11 6= θ0j,1θ0j,2) results in an ellipse-
shaped contour, that is rotated clockwise in case of a positive correlation
(φ0j,11 > θ
0
j,1θ
0
j,2) and counterclockwise with a negative correlation (φ
0
j,11 <
θ0j,1θ
0
j,2).
When prior information is known, it might be possible to use the introduced
properties to make informative choices regarding these parameters. In absence
of prior information however, a reasonable prior distribution of success probabil-
ities θj has a.) a small n
0
j , such that the impact on the decision is limited; and
b.) θj,k =
1
2 , such that successes and failures are equally likely a priori for all
treatments j and all outcomes k. One specific uninformative prior distribution
is Jeffreys' prior, which is well-known for its property to remain invariant under
transformation of parameters. This is useful since our main interest is typically
on the transformed parameters δ rather than the marginal probabilities θj or
the cell probabilities φj , on which the multivariate beta and Dirichlet prior
distributions respectively are specified. For a Dirichlet distribution, Jeffreys'
prior has parameters α0j =
1
2
for all j (Yang and Berger, 1996). When K = 2,
this specification translates to n0j = 2, φ
0
j =
1
4
and θ0j,1 = θ
0
j,2 =
1
2 , such that
prior marginal success probabilities θj,k follow a uniform beta distribution (i.e.
θj,k ∼ Beta(1, 1)). Since φ0j,11 = θ0j,1θ0j,2, the prior correlation ρθj,1,θj,2 equals
zero. As shown in Figure 3b (right panel), Jeffreys' prior results in a relatively
18
flat distribution of δ, conveying little information about the joint treatment
difference a priori.
Prior specification can be generalized to K outcomes. Prior sample size n0j
determines the amount of prior information. Mean prior probabilities of joint
response options φj determine the mean prior marginal probabilities of indi-
vidual treatments (i.e. θ0j = θ
0
1, . . . , θ
0
K), the relation between outcomes k and
l (i.e. ρ0θj,k,θj,l), and the difference between treatments (i.e. δ
0 = δ01 , . . . , δ
0
K).
Similar to the bivariate situation, Jeffreys' prior distribution of δ has parame-
ters α0j =
1
2
(Yang and Berger, 1996). If we reparametrize α0j to n
0φj , n
0
j =
2K−1 and φ0j =
1
2K
. The prior marginal prior success probability θj,k equals
2K−1
2K
= 12 and follows a beta distribution with hyperparameters (2
K−1, 2K−1),
i.e. θj,k ∼ Beta(2K−1, 2K−1). This specification results in a prior correlation of
zero for each variable pair. Although the generalization to K outcomes is math-
ematically straightforward, we remark that estimating these hyperparameters
in practice can be challenging.
4.2 Specification of weights w of the Compensatory deci-
sion rule
To utilize the flexibility and improve the clinical relevance and efficiency of the
Compensatory rule, researchers may wish to specify weights w. The current
subsection discusses two ways to choose these weights.
First, the choice of weight wk for outcome k could be guided by substantive
considerations to reflect the importance of the outcome relative to the other
outcomes. When w = 1
K
, all outcomes are equally important and all success
probabilities in θj exert an identical influence on the weighted success probabil-
ity of treatment j. Any other specification of w that satisfies
∑K
1 wk = 1
implies unequal importance of outcomes. To make this more concrete, let
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us consider two side effects (i.e. K = 2) of brain cancer treatment that are
indicative of qualitive of life: cognitive decline and fatigue (Schimmel et al.,
2018). When setting (wcognition, wfatigue) = (0.50, 0.50), both outcomes would
be considered equally important and a decrease of (say) 0.10 in fatigue could
be compensated by an increase on cognitive functioning of at least 0.10. When
wcognition > 0.50, cognitive decline is more influential than fatigue; and vice
versa when wcognition < 0.50. If wcognition = 0.75 and wfatigue = 0.25 for ex-
ample, the treatment difference of cognitive decline has three times as much
impact on the decision as the treatment difference of fatigue. Thus, depending
on the relative importance of the outcomes, relative weights w can be chosen
accordingly.
Second, weightsw can be specified to potentially improve the efficiency of the
decision. These weights influence the amount of evidence for a treatment differ-
ence in favor of treatment T and affect the decision about treatment superiority
as a result. The efficiency of the Compensatory decision rule can be optimized
with values of w, with w ≥ 0 and ∑Kk=1 wk = 1, that are a priori expected
to maximize the probability of falling in the superiority region. This strategy
could be used when efficiency is of major concern, while researchers do not have
a strong preference for the substantive priority of specific outcomes. Finding
weights that maximize efficiency requires maximizing the following function:
∑
s∗T ,s
∗
C
P (δ ∈ SCompensatory(w)|s∗T , s∗C)× P (s∗T , s∗C |θtrueT ,θtrueC ,ρtrueδk,δl) (17)
=P (δ ∈ SCompensatory(w)|θtrueT ,θtrueC ,ρtrueδk,δl)
where θtrueT and θ
true
C are the treatment effects in the population,
ρtrueδk,δl is the correlation between δk and δl in the population, and
and we sum over all possible configurations of s∗T and s
∗
C ,
which are the anticipated response frequencies before data collection.
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No analytical solution for Equation 17 exists. We can however obtain a
solution for w using large sample theory, which dictates that the posterior dis-
tribution of δ can be approximated with a multivariate normal distribution in
case of a sufficiently large sample. Treatment difference δ = δ1, . . . , δK then has
a K-variate normal posterior distribution with mean µ = (µ1, . . . , µK) and co-
variance matrix Σ. Consequently, the linear combination
∑K
k=1 wkδk has an ap-
proximate normal posterior with mean
∑K
k=1 wkµk and variance
∑K
k=1 w
2
kσ
2
k +
2
∑∑
k<l
wkwlσkl. The probability that
∑K
k=1 wkδk > 0 then follows from the
cumulative normal distribution:
P (
K∑
k=1
wkδk > 0) = 1− Φ
 0−∑Kk=1 wkµk√∑K
k=1 w
2
kσ
2
k + 2
∑∑
k<l
wkwlσkl
 (18)
In practice, the vector of mean treatment differences µ = (µ1, . . . , µK) and
covariance matrix Σ with diagonal elements σ2 = (σ21 , . . . , σ
2
K) and off-diagonal
elements σkl are unknown and often not straightforward to determine directly.
To facilitate the choice of these parameters for the construction of a normal
posterior distribution of δ, we may consider hypothetical datasets of expected
joint response frequencies s∗j for both treatments j. These frequencies can be
used to draw samples from the posterior distributions of φT and φC , which can
subsequently be transformed to a sample of δ as outlined in Section 2. Such a
sample provides estimates of µ, σ2 and σkl, that can be plugged in in Equation
18. We provide an example data configuration for K = 2 in Table 1. This
hypothetical dataset would result in µ = (0.24, 0.08), σ2 = (0.005, 0.005) and
σ12 = −0.002, such that the optimal weights are α = (0.62, 0.38).
The procedure to find efficient weights simplifies when K = 2 and treatment
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Table 1: Example configuration of anticipated joint response frequencies s∗T and
s∗C for approximation of µ,σ
2, and σ12 when K = 2.
s∗T,1 = 1 s
∗
T,1 = 0 s
∗
C,1 = 1 s
∗
C,1 = 0
s∗T,2 = 1 240 300 s
∗
C,2 = 1 80 380
s∗T,2 = 0 380 80 s
∗
C,2 = 0 300 240
differences are uncorrelated, i.e. when covariance σkl equals zero. Maximum ev-
idence is then obtained when weights w are proportional to treatment difference
δ. For example, when δ = (0.30, 0.10), weights w = (0.75, 0.25) are optimal,
such that δ1 and w1 are both three times as large as δ2 and w2.
The two strategies to specify weights may be incompatible: The impact
implied in optimally efficient weights may not fit substantive considerations
of relative importance. An outcome with three times as much impact on the
decision (i.e. weights w = (0.75, 0.25)) may not be three times as important
as outcome the other outcome. It is thus important to carefully consider the
consequences of prioritizing either efficiency or relative importance in the choice
of weights.
4.3 Adaptive design considerations
A common criterion to stop data collection is via an a priori estimated sample
size, for example with the general Bayesian approach outlined in Berry et al.
(2010, Chapter 2). This procedure for trials with a single outcome is based
on the expected treatment difference and the desired error rate. When the
treatment difference can be estimated accurately in advance of data collection,
an a priori estimated sample size may result in an efficient and powerful de-
cision. This is often not the case however, especially when multiple outcomes
are involved. Approaches such as the one discussed by Berry et al. (2010) lend
themselves for extension to multiple outcomes, and several frequentist methods
for sample size estimation with multiple binary outcomes have been developed
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(e.g. Sozu et al., 2010; Whitehead et al., 2010). These approaches have a com-
plexity in common however: The number of unknown parameters increases when
multiple treatment differences and their correlations have to be estimated. This
cumulative uncertainty increases the risk of an ill-chosen sample size and often
makes a priori sample size estimation an inferior strategy for trials with multiple
outcomes (Rauch and Kieser, 2015).
To avoid the problems associated with choosing sample sizes in advance,
we focus on adaptive stopping as an alternative to an a priori fixed sample
size. Adaptive stopping monitors incoming data and terminates data collection
a.) as soon as sufficient evidence to conclude superiority has been obtained,
or b.) when a prespecified maximum sample size has been reached without
a superiority conclusion. This approach is attractive to deal with uncertainty
about treatment differences and their relations, but requires careful design to
achieve proper decision error management (Bauer et al., 2016; Food and Drug
Administration, 2010). Type I errors are especially prone to inflating when
repeated decision-making is used for adaptive stopping (Sanborn and Hills, 2014;
Scho¨nbrodt et al., 2017).
Regulating the following three parameters might help to build an adaptive
design that properly controls Type I errors (Food and Drug Administration,
2010; Jennison and Turnbull, 1999):
1. Increasing the sample size to look at the data for the first time (nj,min)
2. Increasing the number of added participants if the previous analysis did
not provide sufficient evidence (nj,step)
3. Reducing the sample size to stop the trial if evidence is not strong enough
to conclude superiority (nj,max)
A more elaborate treatment of adaptive designs including the choice of these
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parameters is beyond the scope of this paper, but other sources can be consulted
for a more in-depth understanding.
4.4 Calibration of decision threshold pcut
Given the adaptive design parameters discussed in the previous subsection, the
Type I error rate α can be regulated with the choice of decision threshold pcut
(Food and Drug Administration, 2010; Shi et al., 2019). To accomplish this,
we can choose pcut in such a way that any population value of δ outside the
superiority region SSup results in a superiority conclusion in at most 100 × α
percent of the posterior samples of δ. Therefore, we first identify the population
values of δ that result in the largest type I error for a given pcut, and then
calibrate the value of pcut such that the Type I error rate over a large number
of samples equals α.
In classical one-sided significance testing, population values of δ under the
null hypothesis are called the least favorable population values: Values of δ
outside SSup that are most difficult to distinguish from values of δ inside SSup.
Calibrating pcut on these least favorable values implies that the Type I error
rate of all values of δ outside SSup is properly controlled.
The least favorable values typically lie on the boundary of the non-superiority
region. For the specific situation of two outcomes, they can be identified for
different decision rules using the following rules of thumb. When the superiority
region is bound by a straight line, such as the Single or Compensatory rule, the
least favorable values of δ lie on this line. Differently, the Any and All rules have
their superiority region bound by two non-parallel line segments that connect
at the origin. In case of the Any rule, the largest Type I error will be obtained
when δ = (0.0, 0.0). The least favorable values of the All rule satisfy δk > 0
and δl = 0.0, where treatment difference δk should be large enough to minimize
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overlap between the sampling distributions of δ and the origin. Note that the
Type I error rate does not only depend on joint treatment difference δ, but
may be influenced by the correlation between them (i.e. ρδ1δ2). The least
favorable correlation structure is negative for the Any rule, positive for the All
and Compensatory rules, and indifferent for the Single rule. A similar principle
applies in case of more than two outcomes.
After identifying the least favorable values of δ, the value pcut can be chosen
given the specified adaptive design parameters. An algorithm to calibrate pcut
is provided in Appendix A.
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(d) α0j = 5; n
0
j = 20
Figure 3: Bivariate prior distributions of θj (left) and δ = θT − θC (right) for
various specifications of hyperparameters α0j and n
0
j when K = 2.
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Figure 4: The influence of φj on the bivariate beta distribution of θj .
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5 Implementation of the framework
The procedure to arrive at a decision using the multivariate analysis proposed
in Section 2, the decision rules from Section 3 and the design considerations
from Section 4 is the following:
1. Initialization: Choose the following design aspects:
(a) Prior hyperparameters α0j for each treatment j
(b) A decision rule, including weights w in case of a Compensatory rule
(c) The desired Type I error rate
(d) Corresponding adaptive design parameters nj,min, nj,max and nj,step
for each treatment j
(e) Decision threshold pcut
2. Data collection: Collect data until the next interim analysis
3. Computation: Perform Bayesian computation of evidence under the cho-
sen decision rule
(a) For each treatment j, find the posterior hyperparameters of φj by
summing the Q frequencies of unique joint responses xj,i of the first
nj,min cases in sj with prior hyperparameters α
0
j . That is, α
n
j =
α0j + sj .
(b) For each treatment j, obtain L posterior draws, φ
(l)
j , from the cell
probabilities φj |sj ,α0j ∼ Dirichlet(sj +α0j ) , for l ∈ {1, . . . , L}.
(c) Transform the draws to marginal probabilities via θ
(l)
j,1 = φ
(l)
j,11 +φ
(l)
j,10
and θ
(l)
j,2 = φ
(l)
j,11 +φ
(l)
j,01 for {l ∈ 1, . . . , L} to obtain a sample from the
bivariate posterior distribution of θj .
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(d) Transform the draws to outcome specific treatment differences δ
(l)
j,k =
θ
(l)
T,k− θ(l)C,k for all K. These transformed draws reflect a sample from
the distribution of treatment difference δ.
(e) Estimate the posterior probability of treatment superiority for the
decision rule under consideration
P (SSup| . . . ) ≈ L−1
∑
l=1
I(δ(l) ∈ SSup
where I(.) is the indicator function to indicate that the lth draw of
δ is in decision-rule specific superiority region SSup.
Evidence in favor of the decision rule then equals the proportion of
overlap between the distribution of treatment difference δ, and the
superiority region SSup.
4. Conclusion: Make a decision about treatment superiority. If P (Ssup| . . . ) >
pcut, then stop the trial and conclude superiority and register nj,min as
nj,stop. Else, add new cases to the existing sample according to the in-
terim group size, and repeat the procedure with the augmented sample.
Increase the sample until the posterior probability exceeds decision thresh-
old pcut (superiority concluded), or until nj,max is reached (superiority not
concluded).
6 Numerical evaluation
6.1 Simulation setup
The current section illustrates the frequentist decision characteristics of our
framework by means of simulation in the context of two outcomes. We seek
to demonstrate a.) how often the decision procedure results in an (in)correct
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superiority conclusion (i.e. decision error rates) and; b.) how many observations
are required to conclude superiority with satisfactory error rates (i.e. efficiency).
6.1.1 Conditions
The performance of the framework is examined as a function of the following
factors:
1. Treatment differences: We considered eight treatment difference combina-
tions δ, of which an overview is given in Table 2.
2. Correlations between outcomes: For each of the treatment differences,
we investigated three correlations between outcomes ρθj,1,θj,2 : negative:
−0.40, zero: 0.00, and positive: 0.40. These correlations were equal for
both treatments.
These treatment differences and correlation structures results in 8× 3 = 24
different data generating mechanisms. The generated data were evaluated with
six different decision rules. We used the Single, Any, and All rules, as well as
three different Compensatory rules: One with equal weights w = (0.50, 0.50)
and two with unequal weightsw = (0.75, 0.25) andw = (0.62, 0.38). The weight
combinations of the latter two Compensatory rules have been optimized for a
specific scenario with uncorrelated and correlated treatment differences respec-
tively (which we will discuss in more detail in the next paragraph). We refer to
these three Compensatory rules as Compensatory-Equal (C-E), Compensatory-
Unequal Uncorrelated (C-UU) and Compensatory-Unequal Correlated (C-UC)
respectively in the remainder of this section.
The combination of the specified scenarios and decision rules highlights mul-
tiple aspects of the framework. Scenarios 1 and 2 represent true null effects for
each of the decision rules under consideration, in which both treatment differ-
ences were negative (scenario 1; δ = −0.20) or zero (scenario 2; δ = 0.00).
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These scenarios provide insight in the proportion of false superiority conclu-
sions (i.e. the Type I error rate) for the Single, Any, and Compensatory rules.
Scenarios 3 to 5 and 8 reflect true treatment differences on both outcomes
and should result in a superiority conclusion for each decision rule. Scenario
6 (δ = (0.40, 0.00)) represents a true treatment difference on outcome 1 only,
such that all decision rules except the All rule conclude superiority. This Sce-
nario provides insight in the Type I error rate for the All rule. Scenario 7
(δ = (0.20,−0.40)) reflects a positive treatment difference on outcome 1 and
a larger negative treatment difference on outcome 2. The Single, Any, and
Compensatory-Unequal Uncorrelated rule should conclude superiority in this
scenario.
To demonstrate the influence of weights w, we distinguished scenarios with
equal (scenarios 3 to 5) and unequal (scenarios 6 and 8) treatment differences.
For each of these scenarios, one of the decision rules has been specified with effi-
cient weights using the approach in Section 4.2. Scenario 6 maximizes efficiency
for the Single rule, scenarios 3 to 5 for the Compensatory rule with equal weights
(C-E), and scenario 8 for the Compensatory rules with unequal weights (C-UU
& C-UC). Weights w = (0.75, 0.25) are chosen such that treatment differences δ
are proportional to weights w for the treatment difference in scenario 8 with un-
correlated outcomes (i.e. Scenario 8.2). Weights w = (0.62, 0.38) are optimized
for the treatment difference in scenario 8 with negatively correlated outcomes
(i.e. Scenario 8.1). Note that the data generation is based on the correlation
between outcomes within treatment j (ρθj,1,θj,2), while the computation of ef-
ficient weights uses the posterior correlation between two treatment differences
(ρδ1,δ2). These two correlations are related, but not identical: The posterior cor-
relation between treatment differences follows from θT , θC , ρθT,1,θT,2 , ρθC,1,θC,2 ,
α0T and α
0
C and can be approximated using the procedure in Section 4.2.
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Further, we varied the sizes of the (equal) treatment differences in scenarios
3 to 5. A small effect (δ = 0.1, Scenario 3) potentially suffers from a limited
maximum sample size that may be too small to conclude superiority, thereby
differentiating the decision rules on their probability to conclude superiority. In
scenario 4 (δ = 0.2), the maximum sample size was large enough to conclude
superiority in the majority of samples. This scenario allows to compare the
different sample sizes that each rule requires to conclude superiority. Scenarios
3 and 4 can be compared to scenario 5 (δ = 0.4) to illustrate the behavior of
the decision rules under treatment effects of different sizes.
6.1.2 Data generation and evaluation
We generated 5, 000 samples for each of the 24 scenarios in Table 2. These
data were evaluated using the decision procedure outlined in Section 5. We
performed the first interim analysis with nj,min = 5 observations per treatment
and terminated the trial when a treatment difference was detected or when
sample size nj exceeded nj,max = 500 in absence of a superiority conclusion.
We started with nj,step = 1 and increased the interim group size to nj,step = 5
after the first 50 observations per treatment. Increasing the interim group size
while the trial proceeds balances precision of the distribution of nj,stop with
computation time. Small steps are particularly relevant for efficient decision-
making with large treatment effects. In this situation, a small sample might
provide sufficient information to draw a superiority conclusion. Since single ob-
servations are influential in small samples, a single or few extra participant(s)
may provide a considerable chance to change a non-superiority conclusion into a
superiority decision. Small nj,step in the beginning of a trial may then contribute
to a more accurate representation of the average nj,stop for large treatment ef-
fects. Smaller treatment effects require larger sample sizes, such that increasing
the interim group size is a tool to limit the number of interim analyses and keep
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computation time manageable in a simulation setting.
Decision thresholds pcut were calibrated for each decision rule individu-
ally, using the procedure outlined in Section 4.4 and Appendix A. Scenario
2 (δ = (0.00, 0.00)) represented least favorable values of δ for the Single, Any,
and Compensatory rules, while scenario 6 (δ = (0.40, 0.00)) reflected the least
favorable values of δ for the All rule. Given these least favorable values, we used
pcut = 0.9963 for the Single rule, pcut = 0.9998 for the Any rule, pcut = 0.9955
for the All rule, pcut = 0.9968 for the Compensatory rule with equal weights
(C-E), and pcut = 0.9964 and pcut = 0.9967 for the Compensatory rules with
unequal weights (C-UU and C-UC respectively).
6.2 Results
The proportion of samples that concluded superiority and the average nj,stop for
all conditions are presented in Tables 3 and 4 respectively. Scenario 2 resulted
in the desired Type I error for the Single, Any, and Compensatory rules, while
Scenario 6 demonstrated that Type I errors were properly controlled for the All
rule.
In the discussion of the performance we primarily focus on the newly intro-
duced Compensatory rule in comparison to the other decision rules. The results
demonstrate that the Compensatory rule can make decisions efficiently with
acceptable error rates and outperforms the Single and All rules in the majority
of scenarios. The efficiency of the Compensatory rule is particularly apparent
in scenario 3, where δ is small. The rule also benefits from the relation between
outcomes: As intended, our framework can exploit (negative) correlations for
more efficient decision making. Considerable variation in required sample size
due to different correlations can be observed: The average nj,stop (almost) dou-
bles in scenarios with equal treatment differences (e.g. Scenarios 3.1 vs. 3.3 and
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4.1 vs. 4.3).
The results also shed light on two exceptions where the Compensatory rule
may not be the most efficient choice. First, the Any rule in general results
in efficient decisions as well. The practical utility of the Any rule is debat-
able however, since the rule does not include the compensatory mechanism that
facilitates regulation of clinical relevance. The Any rule carries the risk of con-
cluding superiority even in a situation in which a small positive effect may be
outweighed by a larger negative effect (Scenario 7). This is usually undesirable
for the clinical relevance of the decision unless the small positive effect is much
more relevant. The Compensatory rule explicitly takes this into account with
weight specification, explaining the difference betwen C-UU vs. C-E and C-UC
in this scenario. As a second exception, the Compensatory is outperformed by
the Single rule in the scenario with an effect on one outcome only (Scenario 6).
Effectively, in this situation the Single rule is the Compensatory rule with the
optimal weights for this specific scenario w = (1, 0); A situation that is very
unlikely in practice.
Comparison of the three different Compensatory rules further highlights the
influence of weights w and illustrates that a Compensatory rule is - as expected
- most efficient when weights have been optimized with respect to the treatment
differences and the correlation. The Compensatory rule with equal weights (C-
E) is most efficient when treatment differences on both outcomes are equally
large (Scenarios 3 − 5). The Compensatory rule with unequal weights for un-
correlated outcomes (C-UU) is most efficient when the treatment difference is
proportional to the treatment difference and outcomes were uncorrelated (Sce-
nario 8.2). The Compensatory rule with unequal weights, optimized for nega-
tively correlated outcomes (C-UC) is most efficient in scenario 8.1. Utilizing the
flexibility of the Compensatory rule to tailor weights to expected treatment dif-
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ferences and their correlations thus pays off in terms of efficiency. Note however
that optimization provides the best results when the estimates used to specify
weights correspond to the true treatment differences and correlation, which is
of course not always the case in practice.
Despite substantial differences in average nj,stop resulting from the corre-
lation between outcomes and the specification of weights, the Compensatory
rule in general has a better performance than the Single and All rules and is
equivalent to the Any rule, even under the least favorable correlation structure
(i.e. a positive correlation). The rule is the most efficient rule in the majority of
treatment difference scenarios, especially when weights are optimized. Nonethe-
less, even without specification of efficient weights, the Compensatory rule with
equal weights is a safe choice that generally results in efficient decisions.
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Table 2: Simulation conditions
Scenario δ1 δ2 ρθj,1,θj,2 θT,1 θT,2 φT,11 θC,1 θC,2 φC,11
1.1 -0.20 -0.20 -0.40 0.40 0.40 0.06 0.60 0.60 0.26
1.2 0.00 0.16 0.36
1.3 0.40 0.26 0.46
2.1 0.00 0.00 -0.40 0.50 0.50 0.15 0.50 0.50 0.15
2.2 0.00 0.25 0.25
2.3 0.40 0.35 0.35
3.1 0.10 0.10 -0.40 0.55 0.55 0.20 0.45 0.45 0.10
3.2 0.00 0.30 0.20
3.3 0.40 0.40 0.30
4.1 0.20 0.20 -0.40 0.60 0.60 0.26 0.40 0.40 0.06
4.2 0.00 0.36 0.16
4.3 0.40 0.46 0.26
5.1 0.40 0.40 -0.40 0.70 0.70 0.41 0.30 0.30 0.01
5.2 0.00 0.49 0.09
5.3 0.40 0.57 0.17
6.1 0.40 0.00 -0.40 0.70 0.50 0.26 0.30 0.50 0.06
6.2 0.00 0.35 0.15
6.3 0.40 0.44 0.24
7.1 0.20 -0.40 -0.40 0.60 0.30 0.09 0.40 0.70 0.19
7.2 0.00 0.18 0.28
7.3 0.40 0.27 0.37
8.1 0.24 0.08 -0.40 0.62 0.54 0.24 0.38 0.46 0.08
8.2 0.00 0.33 0.17
8.3 0.40 0.43 0.27
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Table 3: P(Conclude superiority) for different treatment differences, correlation
structures, and decision rules. The Type I error rate of the calibration scenario
for each decision rule is printed in bold.
Scenario P(Conclude superiority)
Single Any All C-E C-UU C-UC
1.1 0.001 0.000 0.000 0.000 0.000 0.000
1.2 0.001 0.000 0.000 0.000 0.001 0.000
1.3 0.000 0.000 0.000 0.001 0.000 0.001
2.1 0.046 0.050 0.000 0.042 0.045 0.044
2.2 0.049 0.037 0.000 0.047 0.049 0.049
2.3 0.050 0.022 0.003 0.049 0.049 0.047
3.1 0.808 1.000 0.553 1.000 0.986 0.999
3.2 0.798 0.965 0.585 0.977 0.946 0.973
3.3 0.797 0.856 0.634 0.917 0.893 0.912
4.1 1.000 1.000 1.000 1.000 1.000 1.000
4.2 1.000 1.000 1.000 1.000 1.000 1.000
4.3 1.000 1.000 1.000 1.000 1.000 1.000
5.1 1.000 1.000 1.000 1.000 1.000 1.000
5.2 1.000 1.000 1.000 1.000 1.000 1.000
5.3 1.000 1.000 1.000 1.000 1.000 1.000
6.1 1.000 1.000 0.038 1.000 1.000 1.000
6.2 1.000 1.000 0.047 1.000 1.000 1.000
6.3 1.000 1.000 0.049 1.000 1.000 1.000
7.1 1.000 0.999 0.000 0.000 0.544 0.008
7.2 1.000 0.999 0.000 0.002 0.436 0.015
7.3 1.000 0.999 0.000 0.003 0.363 0.020
8.1 1.000 1.000 0.604 1.000 1.000 1.000
8.2 1.000 1.000 0.621 1.000 1.000 1.000
8.3 1.000 1.000 0.618 1.000 1.000 1.000
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Table 4: Average nstop (SE) for different treatment differences, correlation struc-
tures, and decision rules. For each scenario, the value of the most efficient
decision rule is printed in bold.
Scenario Average nstop
Single Any All C-E C-UU C-UC
1.1 - (-) - (-) - (-) - (-) - (-) - (-)
1.2 - (-) - (-) - (-) - (-) - (-) - (-)
1.3 - (-) - (-) - (-) - (-) - (-) - (-)
2.1 - (-) - (-) - (-) - (-) - (-) - (-)
2.2 - (-) - (-) - (-) - (-) - (-) - (-)
2.3 - (-) - (-) - (-) - (-) - (-) - (-)
3.1 219 (1.97) 110 (1.10) 356 (1.34) 106 (1.06) 152 (1.51) 117 (1.19)
3.2 221 (1.98) 183 (1.70) 324 (1.57) 163 (1.64) 183 (1.78) 168 (1.68)
3.3 217 (1.97) 228 (1.88) 285 (1.78) 196 (1.88) 201 (1.91) 198 (1.90)
4.1 85 (0.89) 32 (0.27) 133 (0.82) 30 (0.25) 44 (0.44) 33 (0.30)
4.2 85 (0.89) 54 (0.52) 126 (0.89) 46 (0.47) 55 (0.57) 48 (0.48)
4.3 84 (0.89) 79 (0.75) 116 (0.93) 61 (0.65) 65 (0.69) 62 (0.66)
5.1 23 (0.21) 11 (0.04) 33 (0.20) 10 (0.04) 13 (0.08) 11 (0.06)
5.2 23 (0.20) 16 (0.11) 31 (0.21) 13 (0.10) 16 (0.13) 14 (0.11)
5.3 23 (0.21) 21 (0.17) 29 (0.23) 17 (0.16) 18 (0.16) 17 (0.16)
6.1 23 (0.21) 24 (0.18) - (-) 29 (0.24) 20 (0.17) 22 (0.17)
6.2 23 (0.21) 32 (0.28) - (-) 44 (0.45) 25 (0.24) 31 (0.30)
6.3 23 (0.21) 37 (0.31) - (-) 59 (0.64) 30 (0.30) 40 (0.42)
7.1 86 (0.91) 148 (1.17) - (-) - (-) 239 (2.09) - (-)
7.2 85 (0.89) 148 (1.17) - (-) - (-) 233 (2.14) - (-)
7.3 86 (0.89) 149 (1.17) - (-) - (-) 227 (2.18) - (-)
8.1 60 (0.61) 44 (0.40) 264 (1.68) 44 (0.42) 43 (0.42) 40 (0.37)
8.2 59 (0.62) 69 (0.66) 250 (1.85) 69 (0.72) 54 (0.57) 58 (0.59)
8.3 60 (0.62) 91 (0.81) 241 (1.94) 94 (1.00) 66 (0.69) 77 (0.82)
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7 Discussion
The current paper provided a Bayesian framework to efficiently combine mul-
tiple binary outcomes into a clinically relevant superiority decision. We high-
lighted three characteristics of the approach:
1. The sensitivity of the decision to the inclusion of multiple outcomes can
be captured by the multivariate Bernoulli-multivariate beta model. When
multiple outcomes are included in the decision, the amount of evidence
in favor of a specific treatment is influenced by the correlation between
outcomes.
2. Statistical decisions can be made in a flexible and efficient way with the
Compensatory rule. Error rates and efficiency are sensitive to the choice
of weights, resulting in the largest amount of evidence when weights w
are optimized with respect to treatment differences δ and the correlation
between them.
3. Since efficiency is influenced by a.) the treatment difference; b.) the corre-
lation between outcomes; and c.) the decision rule, a priori sample sample
size estimation is difficult when these parameters are unknown. The ob-
served interplay between the aforementioned influences demonstrates the
benefit of adaptive stopping when multiple unknowns complicate a priori
sample size estimation.
Some useful future extensions might improve the practical value of our work.
First, the framework could be extended to other types of distributions to ac-
commodate continuous or mixed data, for example. Second, more work should
explore the parameters choices made in the planning stage of the trial. We find
that the current literature does not offer clear guidance on the specification of
adaptive design parameters. Although less relevant for our simulation where
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we aimed at demonstrating the flexiblity and relative efficiency of our frame-
work, properly choosing them is important for trial design in practice however.
Further elaboration on the choice of these parameters would undoubtedly serve
trials that stop data collection adaptively.
Throughout the paper, the bivariate situation (i.e. with two outcomes)
served as an example. Although we presented methods to accommodate more
than two outcomes, two additional remarks concerning their application should
be made. First, the modelling procedure becomes more complex when the num-
ber of outcomes increases, since the number of cells increases exponentially.
Second, the proposed Compensatory rule has a general form where the sum of
outcomes should exceed zero to conclude superiority. With two outcomes, the
outcomes compensate each other directly and the size of a negative effect is
maximized by the size of the positive effect. A decision based on more than two
outcomes might have the - potentially undesirable - consequence of compensat-
ing a single large negative effect by two or more positive effects. Researchers are
encouraged to carefully think about a suitable superiority definition and might
consider additional restrictions to the Compensatory rule, such as a maximum
size of individual negative effects.
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Appendices
A Selecting a decision threshold
One procedure to select a decision threshold pcut is the following:
1. For each decision rule, find the least favorable treatment difference of δ.
For the decision Single, Any, and Compensatory rules, these are δ = 0.
For the All rule, we used δ = (0.40, 0.00).
2. For each treatment j, transform the least favorable treatment difference
of δ to cell probabilities φj , using the steps:
(a) Compute marginal success probabilities via δj,k = θT,k − θC,k
(b) Compute φj,11 using Equation 16
(c) Compute cell probabilities via θj,1 = φj,11 + φj,10 and θj,2 = φj,11 +
φj,01
3. For each treatment, draw a large number (e.g. 1, 000) datasets of size
nj,max from the multinomial distribution with the cell probabilities φj
4. For each sample, apply the decision procedure outlined in Section 5.
5. Find the proportions of samples that satisfy P (Ssup| . . . ) > pcut for the
scenarios specified in Step 1 and select the proportion with the least favor-
able correlation structure (i.e. the highest proportion). If this proportion
satiesfies α, use pcut. If this proportion exceeds α, repeat the procedure
from step 2 with a higher decision threshold pcut. If the selected pro-
portion is lower than α, repeat the procedure from step 2 with a lower
decision threshold pcut.
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